- Home
- IBRX vs MTX Comparison
IBRX vs MTX Comparison
Compare IBRX & MTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- MTX
- Stock Information
- Founded
- IBRX 2014
- MTX 1968
- Country
- IBRX United States
- MTX United States
- Employees
- IBRX N/A
- MTX N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- MTX Major Chemicals
- Sector
- IBRX Health Care
- MTX Industrials
- Exchange
- IBRX Nasdaq
- MTX Nasdaq
- Market Cap
- IBRX 2.4B
- MTX 2.4B
- IPO Year
- IBRX N/A
- MTX 1992
- Fundamental
- Price
- IBRX $4.49
- MTX $80.68
- Analyst Decision
- IBRX Buy
- MTX Strong Buy
- Analyst Count
- IBRX 2
- MTX 1
- Target Price
- IBRX $17.38
- MTX $97.00
- AVG Volume (30 Days)
- IBRX 10.4M
- MTX 162.7K
- Earning Date
- IBRX 11-12-2024
- MTX 10-24-2024
- Dividend Yield
- IBRX N/A
- MTX 0.55%
- EPS Growth
- IBRX N/A
- MTX 138.40
- EPS
- IBRX N/A
- MTX 4.71
- Revenue
- IBRX $7,332,000.00
- MTX $2,124,900,000.00
- Revenue This Year
- IBRX $1,563.18
- MTX N/A
- Revenue Next Year
- IBRX $1,262.20
- MTX $5.22
- P/E Ratio
- IBRX N/A
- MTX $17.13
- Revenue Growth
- IBRX 1218.71
- MTX N/A
- 52 Week Low
- IBRX $3.10
- MTX $60.78
- 52 Week High
- IBRX $10.53
- MTX $90.30
- Technical
- Relative Strength Index (RSI)
- IBRX 46.07
- MTX 55.87
- Support Level
- IBRX $4.57
- MTX $80.45
- Resistance Level
- IBRX $5.08
- MTX $84.07
- Average True Range (ATR)
- IBRX 0.54
- MTX 1.84
- MACD
- IBRX -0.12
- MTX 0.22
- Stochastic Oscillator
- IBRX 3.16
- MTX 59.29
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
About MTX Minerals Technologies Inc.
Minerals Technologies Inc mines, produces, and sells mineral-based products. The firm organizes itself into three segments based on product type. The specialty minerals segment, sells calcium carbonate, limestone, and talc, which is used in the paper, building materials, paint, automotive, and pharmaceutical industries. The refractories segment sells products for steel furnaces. The performance materials segment sells bentonite used in steel alloy casting and household products including cat litter. The majority of revenue comes from the United States.